Peter Kolchinsky portfolio, Q3 2025

RA Capital Management · 13F for the quarter ending Sep 30, 2025

For Q3 2025, RA Capital Management reported $8.1B across 67 US-listed positions, led by ASND (25.2%), RYTM (7.1%) and PCVX (5.3%). Compared with its filing for Q2 2025, Peter Kolchinsky opened 15 new positions, added to 7, reduced 1 and sold out of 11; 43 positions did not change.

The largest purchase was a new position in Nuvalent Inc ($107.8M); the largest sale, the sale of the whole position in DYN ($92.5M).

Reported value
$8.1B
Positions
67
In the top 10
64%
Filed
Nov 14
2025

Key facts

13F portfolio value
$8.1BQ3 2025
Positions
67
Largest holding
ASND 25.2%
New positions
15
Sold out
11
Filed
Nov 14, 2025

Holdings as of (Q3 2025), filed with the SEC on . Changes are measured against the filing for Jun 30, 2025. Every tracked investor's Q3 2025 13F.

Bought and sold in Q3 2025

Peter Kolchinsky: buys and sells in Q3 2025
StockMoveSharesSizeOf portfolio
Nuvalent Incno ticker on file
▲ New+1.25M$107.8M1.33%
Dyne Therapeutics IncDYN▼ Sold out−9.71M$92.5M1.14%
Belite Bio IncBLTE▲ New+875K$64.8M0.80%
Avidity Biosciences Incno ticker on file
▲ Added 19%+1.38M$59.9M0.74%
RxSight IncRXST▼ Sold out−3.7M$48.1M0.59%
Mineralys Therapeutics IncMLYS▲ Added 19%+1.18M$44.6M0.55%
Pepgen IncPEPG▲ Added 88%+9.38M$43.3M0.53%
Tourmaline Bio Incno ticker on file
▼ Sold out−2.54M$40.6M0.50%
LB Pharmaceuticals IncLBRX▲ New+1.78M$28.1M0.35%
Assembly Biosciences IncASMB▲ New+1.02M$26.1M0.32%
Contineum Therapeutics IncCTNM▲ New+2.12M$24.9M0.31%
Invivyd IncIVVD▲ New+17.12M$18.8M0.23%
Enliven Therapeutics IncELVN▼ Sold out−848.99K$17M0.21%
Prime Medicine IncPRME▲ New+3M$16.6M0.20%
Hinge Health IncHNGE▼ Sold out−300K$15.5M0.19%
Rhythm Pharmaceuticals IncRYTM▲ Added 2.2%+120K$12.1M0.15%
Uniqure NVQURE▲ New+200K$11.7M0.14%
Sab Biotherapeutics IncSABS▲ New+4.4M$8.8M0.11%
Edgewise Therapeutics IncEWTX▲ Added 5.3%+525.8K$8.5M0.11%
Inspire Med Systems IncINSP▲ New+114.9K$8.5M0.11%
Omada Health IncOMDA▼ Sold out−400K$7.3M0.09%
Beta Bionics IncBBNX▼ Sold out−500K$7.3M0.09%
10X Genomics IncTXG▼ Sold out−475.34K$5.5M0.07%
Evolent Health IncEVH▲ New+579.05K$4.9M0.06%
Glaukos CorpGKOS▲ New+54.18K$4.4M0.05%
MBX Biosciences IncMBX▼ Sold out−377.84K$4.3M0.05%
Design Therapeutics IncDSGN▲ New+475.7K$3.6M0.04%
Avalo Therapeutics IncAVTX▼ Reduced 29%−270.01K$3.4M0.04%
Protara Therapeutics IncTARA▼ Sold out−1.04M$3.1M0.04%
Exact Sciences Corpno ticker on file
▲ New+54.94K$3M0.04%
Progyny IncPGNY▲ New+96.63K$2.1M0.03%
Acadia Healthcare CompanyACHC▼ Sold out−89.26K$2M0.02%
Scholar Rock Holding CorpSRRK▲ Added 2.7%+30.34K$1.1M0.01%
Solid Biosciences IncSLDB▲ Added 0.00%+100$6170.00%

Holdings at the quarter's end

Peter Kolchinsky holdings, Q3 2025
#StockSectorShare of portfolioValueSharesReported priceHeldSince Q2 2025
1Ascendis Pharma A/SASND · SPONSORED ADRHealth Care25.2%$2B10.28M$198.816+ qtrsNo change
2Rhythm Pharmaceuticals IncRYTMHealth Care7.07%$573.8M5.68M$100.996+ qtrs▲ Added 2.2%
3Vaxcyte IncPCVXHealth Care5.31%$431M11.97M$36.026+ qtrsNo change
4
Avidity Biosciences Incno ticker on file · SH
—4.64%$376.5M8.64M$43.576+ qtrs▲ Added 19%
5
Cidara Therapeutics Incno ticker on file · SH
—3.97%$322.3M3.37M$95.765 qtrsNo change
6Sionna Therapeutics IncSION—3.79%$307.2M10.45M$29.413 qtrsNo change
7
89BIO Incno ticker on file · SH
—3.60%$292.4M19.89M$14.706+ qtrsNo change
8Newamsterdam Pharma CompanyNAMS—3.55%$288.4M10.14M$28.446+ qtrsNo change
9Mineralys Therapeutics IncMLYS—3.42%$277.7M7.32M$37.926+ qtrs▲ Added 19%
10Janux Therapeutics IncJANX—3.37%$273.5M11.19M$24.446+ qtrsNo change
11
Arcellx Incno ticker on file · SH
—3.07%$249.3M3.04M$82.106+ qtrsNo change
12Lenz Therapeutics IncLENZ—2.40%$194.6M4.18M$46.586+ qtrsNo change
13Tyra Biosciences IncTYRA—2.10%$170.7M12.2M$13.996+ qtrsNo change
14Edgewise Therapeutics IncEWTXHealth Care2.08%$169.1M10.43M$16.226+ qtrs▲ Added 5.3%
15Wave Life Sciences LtdWVE—1.64%$133.2M18.2M$7.326+ qtrsNo change
16Septerna IncSEPN—1.62%$131.6M7M$18.814 qtrsNo change
17Dianthus Therapeutics IncDNTHHealth Care1.39%$112.8M2.87M$39.356+ qtrsNo change
18Bicara Therapeutics IncBCAX—1.35%$109.8M6.96M$15.795 qtrsNo change
19GH Research PLCGHRS—1.35%$109.8M7.68M$14.306+ qtrsNo change
20Ars Pharmaceuticals IncSPRY—1.35%$109.2M10.86M$10.056+ qtrsNo change
21
Nuvalent Incno ticker on file
—1.33%$107.8M1.25M$86.481 qtrNew
22Disc Medicine IncIRON—1.28%$104.2M1.58M$66.083 qtrsNo change
23Vor Biopharma IncVOR—1.19%$96.6M1.98M$48.726+ qtrs—
24Fulcrum Therapeutics IncFULC—1.16%$94.1M10.23M$9.206+ qtrsNo change
25Pepgen IncPEPG—1.14%$92.7M20.06M$4.626+ qtrs▲ Added 88%
26Geron CorpGERN—1.02%$82.7M60.38M$1.376+ qtrsNo change
27Taysha Gene Therapies IncTSHA—0.95%$77M23.56M$3.276+ qtrsNo change
28Belite Bio IncBLTE · SHHealth Care0.80%$64.8M875K$74.001 qtrNew
29Climb Bio IncCLYM—0.78%$63.2M31.42M$2.016+ qtrsNo change
30Scholar Rock Holding CorpSRRK · SHHealth Care0.54%$43.5M1.17M$37.244 qtrs▲ Added 2.7%
31Structure Therapeutics IncGPCR · SH—0.52%$42.5M1.52M$28.006+ qtrsNo change
32Monopar Therapeutics IncMNPR—0.51%$41.8M511.21K$81.674 qtrsNo change
334D Molecular TherapeuticsFDMT—0.49%$39.7M4.56M$8.696+ qtrsNo change
34Solid Biosciences IncSLDB—0.44%$35.9M5.81M$6.176+ qtrs▲ Added 0.00%
35
Metsera Incno ticker on file · SH
—0.44%$35.4M675.53K$52.333 qtrsNo change
36Artiva Biotherapeutics IncARTV—0.35%$28.3M9.85M$2.875 qtrsNo change
37LB Pharmaceuticals IncLBRX—0.35%$28.1M1.78M$15.791 qtrNew
38Travere Therapeutics IncTVTXHealth Care0.34%$27.5M1.15M$23.904 qtrsNo change
39Assembly Biosciences IncASMB—0.32%$26.1M1.02M$25.601 qtrNew
40Acumen Pharmaceuticals IncABOS—0.32%$25.5M14.93M$1.716+ qtrsNo change
41Contineum Therapeutics IncCTNM—0.31%$24.9M2.12M$11.751 qtrNew
42Nkarta IncNKTX—0.28%$22.4M10.81M$2.076+ qtrsNo change
43Larimar Therapeutics IncLRMR · SH—0.24%$19.5M6.05M$3.236+ qtrsNo change
44Invivyd IncIVVD · SH—0.23%$18.8M17.12M$1.101 qtrNew
45Tango Therapeutics IncTNGX · SH—0.21%$16.8M2M$8.402 qtrsNo change
46Prime Medicine IncPRME · SH—0.21%$16.6M3M$5.541 qtrNew
47Arcus Biosciences IncRCUS · SH—0.19%$15.5M1.14M$13.603 qtrsNo change
48Acrivon Therapeutics IncACRV—0.19%$15.1M8.34M$1.816+ qtrsNo change
49Werewolf Therapeutics IncHOWL—0.16%$13.2M6.68M$1.976+ qtrsNo change
50Uniqure NVQURE · SH—0.14%$11.7M200K$58.371 qtrNew
51Eledon Pharmaceuticals IncELDN · SH—0.11%$9.2M3.57M$2.594 qtrsNo change
52Jade Biosciences IncJBIO—0.11%$9.2M1.06M$8.632 qtrsNo change
53Sab Biotherapeutics IncSABS—0.11%$8.8M4.4M$2.011 qtrNew
54Inspire Med Systems IncINSP—0.11%$8.5M114.9K$74.201 qtrNew
55CytomX Therapeutics IncCTMX · SH—0.11%$8.5M2.66M$3.193 qtrsNo change
56Avalo Therapeutics IncAVTX—0.10%$8.4M662.97K$12.715 qtrs▼ Reduced 29%
57
Perceptive Cap Solutionsno ticker on file
—0.10%$8M750K$10.606+ qtrsNo change
58Surrozen IncSRZN · SH—0.10%$7.8M602.63K$12.886+ qtrsNo change
59GeneDx Holdings CorpWGS—0.08%$6.3M58.04K$107.742 qtrsNo change
60Adicet Bio IncACET · SH—0.08%$6.1M7.54M$0.81026+ qtrsNo change
61
Newamsterdam Pharma Co NV-27no ticker on file · WTS
—0.07%$5.7M333.33K$17.116+ qtrsNo change
62Evolent Health IncEVH · SH—0.06%$4.9M579.05K$8.461 qtrNew
63Glaukos CorpGKOS · SHHealth Care0.05%$4.4M54.18K$81.551 qtrNew
64Design Therapeutics IncDSGN—0.04%$3.6M475.7K$7.531 qtrNew
65
Exact Sciences Corpno ticker on file · SH
—0.04%$3M54.94K$54.711 qtrNew
66Inflarx NVIFRX · SH—0.03%$2.6M1.97M$1.342 qtrsNo change
67Progyny IncPGNY · SH—0.03%$2.1M96.63K$21.521 qtrNew

By sector

Peter Kolchinsky portfolio by sector, Q3 2025
SectorShare of portfolioValuePositions
Health Care42.8%$3.5B9
No sector on file57.2%$4.6B58

Questions and answers

What did Peter Kolchinsky own in Q3 2025?

RA Capital Management's 13F for Q3 2025 lists 67 positions worth $8.1B. The largest: ASND (25.2%), RYTM (7.1%), PCVX (5.3%), Avidity Biosciences Inc (4.6%), Cidara Therapeutics Inc (4.0%).

What did Peter Kolchinsky buy in Q3 2025?

The largest purchases, by the shares bought at the quarter-end price the filing implies: Nuvalent Inc (new, $107.8M), BLTE (new, $64.8M), Avidity Biosciences Inc (added, $59.9M), MLYS (added, $44.6M), PEPG (added, $43.3M), LBRX (new, $28.1M).

What did Peter Kolchinsky sell in Q3 2025?

The largest sales: DYN (sold out, $92.5M), RXST (sold out, $48.1M), Tourmaline Bio Inc (sold out, $40.6M), ELVN (sold out, $17M), HNGE (sold out, $15.5M), OMDA (sold out, $7.3M).

When was this filing made?

RA Capital Management filed its 13F for the quarter ending Sep 30, 2025 on Nov 14, 2025. A 13F is due within 45 days of the quarter's end, so the positions were already weeks old when it became public.

Learn

Cite this page

Funkfolio, “Peter Kolchinsky portfolio, Q3 2025: RA Capital Management 13F holdings”, data as of 14 November 2025. https://funkfolio.com/gurus/peter-kolchinsky/2025-q3

Underlying data: SEC EDGAR, Form 13F-HR of RA Capital Management (CIK 1346824) for the period ending Sep 30, 2025.

Source: SEC EDGAR, Form 13F-HR for RA Capital Management (CIK 1346824), period ending Sep 30, 2025, filed Nov 14, 2025. Changes compare share counts with the filing for Jun 30, 2025; a share split in between is allowed for where one is on record. “Reported price” is a position's reported value divided by its shares. The size of a buy or sell is the change in shares at that price; a position sold out is sized at its value in the previous filing, and “of portfolio” sets the size against the $8.1B reported for this quarter. “Held” counts consecutive quarterly filings up to this one, out of the 6 looked at from here back. Sectors are those of the ranked companies on this site as they stand today. Not a live portfolio and not advice.